545 related articles for article (PubMed ID: 8946941)
1. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
[TBL] [Abstract][Full Text] [Related]
2. Effects of phosphodiester and phosphorothioate antisense oligodeoxynucleotides on cell lines which overexpress c-myc: implications for the treatment of Burkitt's lymphoma.
Williams SA; Gillan ER; Knoppel E; Buzby JS; Suen Y; Cairo MS
Ann Oncol; 1997; 8 Suppl 1():25-30. PubMed ID: 9187425
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
[TBL] [Abstract][Full Text] [Related]
4. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus and Burkitt's lymphoma.
Magrath I; Jain V; Bhatia K
Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
[TBL] [Abstract][Full Text] [Related]
6. Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging.
Bergan R; Hakim F; Schwartz GN; Kyle E; Cepada R; Szabo JM; Fowler D; Gress R; Neckers L
Blood; 1996 Jul; 88(2):731-41. PubMed ID: 8695822
[TBL] [Abstract][Full Text] [Related]
7. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells.
Ginobbi P; Geiser TA; Ombres D; Citro G
Anticancer Res; 1997; 17(1A):29-35. PubMed ID: 9066627
[TBL] [Abstract][Full Text] [Related]
8. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
[TBL] [Abstract][Full Text] [Related]
9. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
Habel ME; Lemieux R; Jung D
J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
[TBL] [Abstract][Full Text] [Related]
10. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
[TBL] [Abstract][Full Text] [Related]
11. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
12. c-myc Suppression in Burkitt's lymphoma cells.
Simonsson T; Henriksson M
Biochem Biophys Res Commun; 2002 Jan; 290(1):11-5. PubMed ID: 11779125
[TBL] [Abstract][Full Text] [Related]
13. Anti-IgM-mediated regulation of c-myc and its possible relationship to apoptosis.
Kaptein JS; Lin CK; Wang CL; Nguyen TT; Kalunta CI; Park E; Chen FS; Lad PM
J Biol Chem; 1996 Aug; 271(31):18875-84. PubMed ID: 8702548
[TBL] [Abstract][Full Text] [Related]
14. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
15. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
Wolf J; Pawlita M; Bullerdiek J; zur Hausen H
Cancer Res; 1990 May; 50(10):3095-100. PubMed ID: 2159373
[TBL] [Abstract][Full Text] [Related]
16. Reduction of cisplatin cytotoxicity on human lung cancer cell lines with N-myc amplification by pretreatment with N-myc antisense oligodeoxynucleotides.
Mizushima Y; Kashii T; Kobayashi M
Anticancer Res; 1995; 15(1):37-43. PubMed ID: 7733638
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells.
Broaddus WC; Chen ZJ; Prabhu SS; Loudon WG; Gillies GT; Phillips LL; Fillmore H
Neurosurgery; 1997 Oct; 41(4):908-15. PubMed ID: 9316053
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides.
Bennett MR; Anglin S; McEwan JR; Jagoe R; Newby AC; Evan GI
J Clin Invest; 1994 Feb; 93(2):820-8. PubMed ID: 8113414
[TBL] [Abstract][Full Text] [Related]
19. Regulation of c-fgr proto-oncogene expression in Burkitt's lymphoma cells: effect of interferon treatment and relationship to EBV status and c-myc mRNA levels.
Sharp NA; Luscombe MJ; Clemens MJ
Oncogene; 1989 Aug; 4(8):1043-6. PubMed ID: 2548145
[TBL] [Abstract][Full Text] [Related]
20. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.
Hummel M; Bentink S; Berger H; Klapper W; Wessendorf S; Barth TF; Bernd HW; Cogliatti SB; Dierlamm J; Feller AC; Hansmann ML; Haralambieva E; Harder L; Hasenclever D; Kühn M; Lenze D; Lichter P; Martin-Subero JI; Möller P; Müller-Hermelink HK; Ott G; Parwaresch RM; Pott C; Rosenwald A; Rosolowski M; Schwaenen C; Stürzenhofecker B; Szczepanowski M; Trautmann H; Wacker HH; Spang R; Loeffler M; Trümper L; Stein H; Siebert R;
N Engl J Med; 2006 Jun; 354(23):2419-30. PubMed ID: 16760442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]